Chemotherapy
560 articles
ASCO 2023: Pancreatic Cancer Research Update
The pancreatic cancer research reports from ASCO 2023 focused on different chemotherapy combinations, including immunotherapy.
Vigilance in Pursuing Symptoms Leads to Early Diagnosis
Jay Buth was very persistent in pursuing the reason for his symptoms. That led to a diagnosis of early stage pancreatic cancer.
Pancreatic Cancer Research Highlights from ASCO Annual Meeting
The 2025 ASCO meeting featured pancreatic cancer research including a new treatment modality and a new treatment combination.
My Most Challenging Race
Eric Lasner faced Whipple surgery, chemotherapy with FOLFIRINOX, and radiation, in order to get back to closed circuit road racing.
Pancreatic Cancer Research Updates from ASCO 2024
Learn about the latest developments in pancreatic cancer research into immunotherapy and chemotherapy from the ASCO 2024 meeting.
Canadian Study NeoPancONE Focuses on Biomarker Validation
Dr. Jennifer Knox is leading the NeoPancONE trial for a biomarker that indicates which patients will respond better to certain chemotherapy before surgery.
Why You Need This Simple Blood Test at Diagnosis
An important factor in determining which treatment to use for pancreatic cancer patients is measuring the level of tumor marker CA-19-9. Learn more here.
Picking a Clinical Trial for Pancreatic Cancer Treatment
When Robert Weker was diagnosed with pancreatic cancer, he believed a clinical trial was his best chance of reducing the tumor enough for a Whipple.
Advances in Pancreatic Neuroendocrine Tumor (PNET) Treatments
Dr. Diane Reidy-Lagunes outlines the current state of treatments for pancreatic neuroendocrine tumors (PNETs).
Reeducating Myself About Pancreatic Cancer
Martin Hynes knew all about pancreatic cancer–as a research director he worked on the development of Gemzar. He was able to have a Whipple and is doing well.
PARP Inhibitors for Pancreatic Cancer Maintenance Treatment
Dr. Kim Reiss Binder is leading a clinical trial of maintenance treatment with the PARP inhibitor rucaparib, for patients who carry the BRCA mutation.
Cherishing the Simple Things
Elizabeth O’Connor has a PALB2 genetic mutation so her stage IV pancreatic cancer has responded to immunotherapy.
Pancreatic Cancer: 2018 Highlights And Looking Forward to 2019
Dr. Allyson Ocean leads an overview of the new treatments and protocol from 2018 as well as what are the next steps in treatment for 2019.
Reimagining the Possible to Survive Stage IV Pancreatic Cancer
Marisa Harris was given a devastating diagnosis of stage IV pancreatic cancer. She tapped the power within herself, as well as chemotherapy, to become a long-term survivor.